MST1 and Alzheimer disease: This review highlights recent research that addresses whether Hippo signaling is dysregulated in AD; how this dysregulation interacts with AD-relevant pathological changes; and emerging studies exploring the therapeutic potential of Hippo signaling inhibition, with a particular focus on MST1/2 inhibition, in AD.